[Research Advances of m⁶A RNA Methylation in Non-small Cell Lung Cancer]

Area of Science:

• Molecular Biology
• Epigenetics
• Oncology

Background:

• N6-methyladenosine (m⁶A) is a prevalent mRNA modification in eukaryotes.
• m⁶A RNA methylation involves writers, erasers, and readers, regulating RNA processing.
• m⁶A modification is increasingly implicated in the pathogenesis and progression of non-small cell lung cancer (NSCLC).

Purpose of the Study:

• To review the role of m⁶A RNA methylation in NSCLC.
• To explore m⁶A modulators and their impact on cancer progression.
• To highlight the potential of m⁶A as a biomarker for NSCLC diagnosis and prognosis.

Main Methods:

• Literature review of recent reports on m⁶A function and modulators in NSCLC.
• Analysis of m⁶A's involvement in key cancer hallmarks.
• Examination of m⁶A dysregulation in clinical NSCLC samples and circulating tumor cells.

Main Results:

• m⁶A modification influences NSCLC cell survival, proliferation, migration, invasion, metastasis, and drug resistance.
• Expression of m⁶A and related proteins is altered in NSCLC patients.
• m⁶A alterations are observed in circulating tumor cells (CTCs) of lung cancer patients.

Conclusions:

• m⁶A RNA methylation is a critical factor in NSCLC development and progression.
• m⁶A modification holds promise as a novel biomarker for early NSCLC diagnosis and prognosis.
• Understanding m⁶A regulation can inform new therapeutic strategies and drug development for NSCLC.